EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Analysis of the influence of renal replacement therapy on the development of carbohydrate metabolism disorders and glycemia variability in patients with chronic kidney disease

T. N. Markova, V. O. Yavorskaya, A. I. Ushakova, V. A. Berdinsky, T. V. Ibragimova, L. A. Kumakhova, A. D. Orlova, S. S. Usatiuk

Diabetes mellitus · 2025-05-23 · 28 (2) · 164-174

DOI: 10.14341/dm13194 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND: Dialysis treatment is a risk factor for the development of carbohydrate metabolism disorders (CMD) and glycemia variability (VG) in patients with chronic kidney disease (CKD). AIM: To analyse the impact of renal replacement therapy (RRT) on the development of CMD in patients with CKD without a history of diabetes mellitus (DM). MATERIALS AND METHODS: 90 patients were examined with CKD without DM in the history (60 patients with CKD on RRT using program hemodialysis (pHD) and continuous ambulatory peritoneal dialysis (CAPD) and 30 patients with CKD 3–5 (without RRT)). Patients were collected anamnesis, measured the level of glycated hemoglobin (HbA1c), fasting plasma glucose (FPG) and capillary blood glucose at 5 points in the HD and advanced CKD stages groups and at 9 points in the CAPD group. Indices of VG and dynamics of the glucose median for Friedman in all groups were evaluated. Patients with impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), IGT and FPG, with first diagnosed DM were included in the CMD. RESULTS: In the total group (n=90), the median HbA1с was 5,1 [4,9; 5,4] %, median FPG was 5,2 [4,72; 5,94] mmol/L, and median postprandial glycemia (PPG) was 6,0 [5,5; 6,8] mmol/L. 32,2% (n=29) patients of the total group had CMD: first-diagnosed DM — 2,2% (2 patients), IFG and IGT — 3,3% (3 patients), IFG — 17,8% (16 patients), IGT — 8,9% (8 patients). The prevalence of CMD in the total group was higher according to FPG and/or PPG level than according to HbA1c value (31,3% vs 10%, p

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →